Anticoagulation therapy in non-valvular atrial fibrillation in the COVID-19 era: is it time to reconsider our therapeutic strategy?

Eur J Prev Cardiol. 2022 Nov 8;29(15):2069-2071. doi: 10.1093/eurjpc/zwab021.
No abstract available

MeSH terms

  • Anticoagulants / adverse effects
  • Atrial Fibrillation* / complications
  • Atrial Fibrillation* / diagnosis
  • Atrial Fibrillation* / drug therapy
  • COVID-19*
  • Humans
  • Stroke*
  • Warfarin

Substances

  • Anticoagulants
  • Warfarin